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The Viral Polymerase Inhibitor 2=-C-Methylcytidine Inhibits Norwalk
Virus Replication and Protects against Norovirus-Induced Diarrhea
and Mortality in a Mouse Model
Joana Rocha-Pereira,a Dirk Jochmans,b Yannick Debing,b Erik Verbeken,c Maria S. J. Nascimento,a Johan Neytsb
Laboratório de Microbiologia, Departamento de Ciências Biológicas, Faculdade de Farmácia, Universidade do Porto, Porto, Portugala; Rega Institute for Medical Research,
University of Leuven, Leuven, Belgiumb; Department of Imaging & Pathology, University of Leuven, Leuven, Belgiumc
Human noroviruses are a major cause of food-borne illness, accountable for 50% of all-etiologies outbreaks of acute gastroen-
teritis (in both developing and developed countries). There is no vaccine or antiviral drug for the prophylaxis or treatment of
norovirus-induced gastroenteritis. We recently reported the inhibitory effect of 2=-C-methylcytidine (2CMC), a hepatitis C virus
polymerase inhibitor, on the in vitro replication of murine norovirus (MNV). Here we evaluated the inhibitory effect of 2CMC
on in vitro human norovirus replication through a Norwalk virus replicon model and in a mouse model by using AG129 mice
orally infected withMNV. Survival, weight, and fecal consistency were monitored, and viral loads in stool samples and organs
were quantified. Intestines were examined histologically. 2CMC reduced Norwalk virus replicon replication in a dose-dependent
manner and was able to clear cells of the replicon. Treatment of MNV-infected AG129mice with 2CMC (i) prevented norovirus-
induced diarrhea; (ii) markedly delayed the appearance of viral RNA and reduced viral RNA titers in the intestine, mesenteric
lymph nodes, spleen, lungs, and stool; (iii) completely prevented virus-inducedmortality; and (iv) resulted in protective immu-
nity against a rechallenge. We demonstrate for the first time that a small-molecule inhibitor of norovirus replication protects
from virus-induced disease andmortality in a relevant animal model. These findings pave the way for the development of potent
and safe antivirals as prophylaxis and therapy of norovirus infection.
Humannoroviruses are the leading cause of food-borne diseaseand are responsible for 50% of the acute gastroenteritis
outbreaks that occur worldwide. Diarrheal diseases are associated
with high mortality rates in the developing world, where norovi-
ruses are annually responsible for 200,000 deaths of children un-
der 5 years of age (1). They affect people of all ages, and their
importance in children begins to surpass that of rotavirus since
vaccination against the latter pathogen becomes more and more
widespread (2, 3). Among young children, the elderly, or the im-
munocompromised, norovirus disease may be severe and pro-
longed, eventually leading to hospitalization (71,000/year in the
United States) and/or evolving into chronic gastroenteritis (4).
The burden of norovirus disease is best understood by adding
up the unique features of this enteric pathogen: (i) its highly in-
fectious nature (18 virus particles are sufficient for infection); (5);
(ii) shedding in stool for 20 to 40 days, on average (10 times the
meanduration of illness), also in asymptomatic individuals; (6, 7);
(iii) long persistence in the environment (resistance to disinfec-
tants, heating, and freezing), up to 2 weeks on surfaces; (8); and
(iv) itsmany routes of transmission, including contaminated food
and water (at the source or by food handlers), fomites, recre-
ational waters, or aerosolized particles from vomitus or stool.
Outbreaks of norovirus gastroenteritis thus occur in semiclosed
environments such as long-term care facilities (50%), schools,
restaurants, hospitals, and cruise ships and can scale up to hun-
dreds of sick individuals. Prevention and control of such episodes
depend on the use of disinfectants and hand sanitizers to contain
virus spreading and electrolyte replenishment for dehydrated in-
dividuals. There are no vaccines or antiviral drugs available. Po-
tent and safe antiviral strategies for the treatment and prophylaxis
of norovirus infections may help to reduce the severity of disease
in infected patients and reduce the chance of transmission and
might be used prophylactically to prevent infection during an out-
break.
Since human noroviruses are not cultivatable in vitro, the Nor-
walk virus (a human genogroup I.1 [GI.1] norovirus) replicon-
bearing cell line and the surrogate murine norovirus (MNV) (a
GV norovirus) are the available models that can be used to dis-
cover antivirals against norovirus (9, 10). It was very recently re-
ported that intraperitoneal infection of BALB/c Rag-yc-deficient
mice with human norovirus (GII.4 strain) results in subclinical
infection of the mice with the virus (11). The Norwalk virus rep-
liconmodel was constructed by the insertion of a neomycin phos-
photransferase gene into a plasmid containing the Norwalk virus
genome, which was then transfected into mammalian cell lines
(9). The neomycin gene acts as a selectionmarker and stops trans-
lation. Hence, only the nonstructural proteins (NS1 to NS7) are
translated. These transfected cell lines are capable of constitutively
replicating the viral RNA genome and expressing the replicative
enzymes and other nonstructural proteins of the Norwalk virus
(9). MNV replicates in mice, is transmitted by the fecal-oral route
after being shed in feces, and produces pathophysiological events
comparable to those of norovirus infection in humans (10, 12).
Immunocompetent mice show a persistent asymptomatic infec-
tion when infected with the majority of MNV strains. However,
MNV-1 results in an acute and lethal infection in mice lacking
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components of innate immunity, such as signal transducer and
activator of transcription 1, the recombination-activating gene, or
alpha/beta interferon (IFN-/) and IFN- receptors (13–15).
For this study, we used the MNV-1.CW3 strain to infect IFN-/
and IFN- receptor-deficient AG129 mice. These AG129 mice
have, among others, been used as a small-animalmodel for studies
of vaccine against the dengue virus (16).
We reported recently that the hepatitis C virus (HCV) nucleo-
side polymerase inhibitor 2=-C-methylcytidine (2CMC) inhibits
the in vitro replication of MNV (17). We report here that 2CMC
also inhibits the replication of the Norwalk virus replicon and is
able to cure cells of the replicon. We further demonstrated that
2CMC protects AG129 mice against MNV-induced disease and
death. To the best of our knowledge, this study constitutes the first
evidence that a small-molecule inhibitor of norovirus replication
protects (in a relevant animal model) against virus-induced diar-
rhea and death.
MATERIALS AND METHODS
Cells, viruses, and compound. 2CMC was synthesized as previously de-
scribed (18). For in vitro assays, a stock solution of 2CMCwas prepared in
dimethyl sulfoxide. For in vivo assays 2CMCwas dissolved in sterile saline.
Strain MNV-1.CW3 (kindly provided by Herbert Virgin, Washington
University, St. Louis, MO) was propagated in RAW 264.7 cells (ATCC,
Barcelona, Spain) grown in Dulbecco’s modified Eagle’s medium
(DMEM; Life Technologies, Ghent, Belgium) supplemented with 10%
fetal bovine serum (FBS), 2mML-glutamine, 20mMHEPES, 0.075 g/liter
sodium bicarbonate, 1 mM sodium pyruvate, 100 U penicillin/ml, and
100 g/ml streptomycin at 37°C in a humidified atmosphere of 5% CO2.
Virus stocks were generated from their sixth passage in cell culture, and
viral titers were determined by endpoint titration. HG23 cells (Norwalk
virus replicon-bearing Huh-7 cell origin) (9) were grown in DMEM sup-
plementedwith 10%FBS, 2mML-glutamine, 20mMHEPES, 0.075 g/liter
sodium bicarbonate, 100 U penicillin/ml, 100 g/ml streptomycin, and
1.25 mg/ml Geneticin (G418; Life Technologies) at 37°C in a humidified
atmosphere of 5% CO2.
Antiviral assay. The in vitro antiviral activity of 2CMC was evaluated
by quantification of intracellular Norwalk virus replicon RNA and the
-actin mRNA reference (housekeeping) gene (by quantitative reverse
transcription-PCR [qRT-PCR]).
HG23 cells (5,000/well) were seeded into the wells of 96-well plates
in complete DMEM without G418. After 24 h of incubation, serial
dilutions of compounds were added. Cells were further incubated for
72 h, after which cell culture supernatant was removed and monolay-
ers were washed with phosphate-buffered saline (PBS). Cell monolay-
ers were collected for RNA load quantification by qRT-PCR. To deter-
mine relative levels of Norwalk virus replicon RNA, -actin was used
as a normalizer and ratios were calculated by the Pfaffl method (19).
The Norwalk virus replicon/-actin ratio was calculated as follows:
Ratio  ENorwalk
CT, Norwalk (CC 	 TC)/E-actin
CT, -actin (CC 	 TC),
where ENorwalk and E-actin represent the amplification efficiencies
(E 10	1/slope) of the Norwalk virus replicon and -actin qRT-PCRs,
respectively; CT, Norwalk virus (CC 	 TC) is the CT (threshold
cycle) of untreated control cells (CC)minus the CT of cells treated with
a compound concentration (TC) obtained with Norwalk virus repli-
con primers and probe; and CT, -actin (CC 	 TC) is the CT of
untreated control cells (CC) minus the CT of cells treated with a com-
pound concentration (TC) obtained with -actin primers and probe.
Efficiency values (ENorwalk and E-actin) were determined for each qRT-
PCR. The 50% effective concentration (EC50) and EC90 were defined as
the compound concentrations that resulted in 50 and 90% reductions
of the relative Norwalk virus replicon RNA levels.
Clearance rebound assay. HG23 cells were seeded at 2.5 
 105/25-
cm2 T flask with complete DMEM and 1.25 mg/ml G418. After 24 h of
incubation, the cell culture medium was replaced with complete DMEM
without G418 containing either one fixed concentration of 2CMC or no
antiviral compound. Selected concentrations of 2CMC (6.25 to 25g/ml)
were up to 5 times the EC50 butwere not cytostatic.When 90%confluence
was reached, cultures were trypsinized and (i) 2.5
 105 cells were seeded
into a new 25-cm2 T flask in complete DMEM with the same concentra-
tion of compound and (ii) 1.5 
 105 cells from each flask were washed
with PBS and collected for quantification of the Norwalk virus replicon
and -actin RNA contents. Cells were passaged a total of six consecutive
times in the presence or absence of 2CMC and in the absence of G418
(clearance phase). For Norwalk virus replicon/-actin ratio calculations,
each passage of 2CMC-treated cells was compared to untreated control
cells with the same passage number. Every 2 passages (after passages 2, 4,
and 6), cells from each flask were passaged three consecutive times in the
presence of 1.25 mg/ml G418 and in the absence of the compound (re-
bound phase). Also here 2.5 
 105 cells were seeded into new 25-cm2 T
flasks and 1.5 
 105 cells from each flask were washed with PBS and
collected for quantification of Norwalk virus replicon and -actin RNA
contents by qRT-PCR.
Assessment of antiviral activity in an MNV-infected mouse model.
AG129 mice (129/Sv mice deficient in both alpha/beta interferon [IFN-
/] and IFN- receptors) were bred and housed at the Rega Institute
under specific-pathogen-free conditions. All experiments were per-
formed under the guidelines and with the authorization of the Ethical
Committee of the KU Leuven (P101/2012).
For all experiments, age- and sex-matched mice 6 to 8 weeks of age
were infected by oral gavage with 3
 106 50% cell culture infectious dose
(CCID50) of MNV (total volume of 200 l). Treatment with 2CMC was
initiated 1 h before infection with a dose of 100 mg/kg/day divided into
two daily treatments (2
 50 mg/kg) for 7 consecutive days by the subcu-
taneous route (n 15). Salinewas administered to untreated controlmice
on the same schedule as 2CMC(n 12). Treated and untreatedmicewere
kept separate in independently ventilated cages for all of the experiments.
Bedding was replaced once a week. Starting at day 0 postinfection (p.i.),
mice were weighed daily and stool samples were collected from each ani-
mal and scored for consistency (0, normal feces; 1, mixed stool samples
containing both solid and pasty feces; 2, pasty feces; 3, semiliquid feces; 4,
liquid feces). When animals were severely ill, they were humanely eutha-
nized with pentobarbital (Nembutal). Blood was collected by cardiac
puncture. Following extensive transcardial perfusion with PBS, 100 to
150mg of organ tissue (small intestine, proximal colon,mesenteric lymph
nodes, spleen, and lung) was either fixed in 4% formaldehyde for later
histological examination or collected in 2-ml tubes containing 2.8 mm
zirconium oxide beads (Precellys/Bertin Technologies) for quantification
of viral RNA by qRT-PCR. To these, RLT lysis buffer (Qiagen, The Neth-
erlands) was added and tissue homogenates were prepared with an auto-
mated homogenizer (Precellys24; Bertin Technologies). Homogenates
were cleared by centrifugation, and total RNA was extracted from the
supernatant. For histological examination, organ tissue was embedded in
paraffin, sectioned, and stained with hematoxylin and eosin (H&E).
RNA isolation and qRT-PCR. To extract RNA from mouse organs
and stool samples, as well as from HG23 cells, the RNeasy minikit (Qia-
gen) was used according to the manufacturer’s protocol. For detection of
Norwalk virus replicon RNA, forward (5=-CCG GCT ACC TGC CCA
TTC-3=) and reverse (5=-CCA GAT CAT CCT GAT CGA CAA G-3=)
primers and a probe (5=–6-carboxyfluorescein–ACA TCG CAT CGA
GCG AGC ACG TAC–6-carboxytetramethylrhodamine–3=) for the neo-
mycin gene were used as previously described (20). For detection of -ac-
tin mRNA, forward (5=-GGC ATC CAC GAA ACT ACC TT-3=) and re-
verse (5=-AGC ACT GTG TTG GCG TAC AG-3=) primers and a probe
(5=–6-hexachlorofluorescein–ATCATGAAGTGTGACGTGGACATC
CG–Black Hole Quencher 1–3=) were used as previously described (21).
ForMNVqRT-PCR, the primers and probe were used as described before
(22).
One-step qRT-PCRwas performedwith a 25-l reactionmixture con-
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taining 12.5l of One-Step Reverse Transcriptase qPCRMaster Mix Plus
Low ROX (Eurogentec), 0.125 l of an RT-PCR enzyme mixture, 5 l of
template RNA, and 300 nM Norwalk virus replicon primers and probe,
300 nM-actin primers and 200 nMprobe, or 900 nMMNVprimers and
200 nM MNV probe. Cycling conditions were RT at 48°C for 30 min,
initial denaturation at 95°C for 10 min, and 40 cycles of denaturation at
95°C for 15 s, annealing, and extension at 60°C for 1 min (ABI 7500 Fast
Real-Time PCR System; Applied Biosystems). For absolute MNV quanti-
fication, standard curves were generated by using 10-fold dilutions of a
known concentration of MNV template DNA.
Statistical analysis. All data were analyzed with Prism 5 software
(Graph-Pad Software, San Diego, CA). The D’Agostino and Pearson om-
nibus normality test was performed. In all graphs, *** indicates a P value
of0.001, ** indicates a P value of0.01, * indicates a P value of0.05,
andNS indicates no statistically significant difference (P 0.05). P values
were determined with an unpaired t test (with n  8 and a Gaussian
distribution) or a nonparametric Mann-Whitney test (with n  8 or a
non-Gaussian distribution). The one-sample t test was used to compare
means to the limit of detection (LOD). All error bars depict the standard
errors of the means (SEM). Grubbs’ test was used to detect significant
outliers (P 0.01).
RESULTS
2CMC inhibits the in vitro replication of human norovirus.The
inhibitory effect of 2CMC on human norovirus replication was
evaluated by using the Norwalk virus replicon system. The reduc-
tion of Norwalk virus RNA in the presence of 2CMC was quanti-
fied by qRT-PCR and normalized to -actin mRNA levels. 2CMC
reduced levels ofNorwalk virus RNA in a dose-dependentmanner
with an EC50 of 4.7 1.0g/ml (18 4M) and an EC90 of 22
5 g/ml (84 19 M) (Fig. 1B). The effect of 2CMC on the host
cell was monitored by quantifying the effect of the compound on
the housekeeping gene for-actin. At 2CMCconcentrations of up
to 100 g/ml, a CT of 1 was observed with -actin (Fig. 1A).
Hence, 2CMC inhibits the Norwalk virus replicon at concentra-
tions without significant cytotoxicity.
2CMC clears cells of the Norwalk virus replicon. To evaluate
whether 2CMC is able to completely eliminate the norovirus rep-
licon from host cells, clearance and rebound experiments were
performed. For the clearance phase, cells were treated for six con-
secutive passages with 2CMC in the absence of G418 selective
pressure. In cells treated with 25g/ml 2CMC (5 times the EC50),
Norwalk virus replicon levels were reduced by 5 log10 after four
passages (at 6.25 and 12.5 g/ml, 2 log10 was the maximum ob-
served reduction) (Fig. 2A). Additionally, in untreated control
cells, the variation in the quantity of Norwalk virus RNA (and
-actinmRNA) among the six different passages was2CT units.
This further attests that the Norwalk virus replicon levels are rel-
atively stable during passaging of the replicon-containing cul-
tures. For the rebound phase, 2CMCwas omitted from the culture
medium but cells were again cultured under the selective pressure
of G418. When cultures are successfully cleared of the replicon,
they lose the ability to grow in the presence of the selectionmarker
G418. When the drug does not clear the cells of the replicon, the
cultures survive and proliferate in the presence of G418. Cultures
that had been treated for 4 or 6 passages with 25 g/ml 2CMC
were no longer able to proliferate in the presence of G418 (Fig. 2).
Hence, 2CMC at 25 g/ml (but not at lower concentrations) is
able to clear cells of the replicon following four consecutive pas-
sages of antiviral pressure.
2CMC protects AG129 mice against MNV-induced diarrhea
and death. AG129mice were infected orally withMNV 1 h after a
first dose (50 mg/kg) of 2CMC or vehicle was given. Treatment
was continued twice daily for 7 consecutive days. The first signs of
disease in the infected, vehicle-treated group appeared at 3 days
p.i.;mice became lethargic and had a hunched posture, ruffled fur,
andwatery squinted eyes. The severity of disease increased rapidly,
culminating in a mean time to death or euthanasia of 3.5  0.5
days p.i. (Fig. 3). Macroscopic observation of the abdominal cav-
ities of untreated mice revealed gastric bloating (data not shown).
All of the animals in the 2CMC-treated group survived the infec-
tion (Fig. 3).Mice exhibited somewhat lethargic behavior and had
moderately ruffled fur on days 5 and 6 p.i. but appeared healthy
and active on other days.
FIG 1 Antiviral activity of 2CMC against the Norwalk virus replicon. HG23 cells were exposed to serial concentrations of 2CMC for a period of 72 h, after which
cell monolayers were collected for quantification of RNA loads by qRT-PCR. Intracellular RNA loads are represented by the variation in Norwalk virus replicon
and -actinCT values (A) and by relative genome quantification of the Norwalk virus replicon versus -actin (B). Dotted lines represent 50 and 90% reductions
of the relative Norwalk virus replicon RNA levels. Results are mean values SEM of five independent experiments.
Rocha-Pereira et al.
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Between days 2 and 4 p.i., untreatedmice lost 14.5% 0.6%of
their body weight while the weight of 2CMC-treated mice de-
creased 7.2%  1% (Fig. 4). The 2CMC-treated animals contin-
ued to lose weight up to 6 days p.i., with amaximumweight loss of
13.9% 1.5%. As of day 7 p.i., these mice started to regain body
weight and recovered all of the lost weight by 11 days p.i. (Fig. 4).
Untreated mice became diarrheic at day 3 p.i., with a stool score
that increased to 4 (liquid stool) at 4 days p.i. (Fig. 5). The fecal
consistency score of 2CMC-treatedmice wasmarkedly and signif-
icantly lower than that of vehicle-treated animals, and a majority
of the stool samples of the treated mice had a more or less normal
consistency and appearance during the entire duration of the ex-
periment (Fig. 5). Treatment with 2CMC was stopped at 7 days
p.i. Mice were then kept for 21 days (following the cessation of
treatment with 2CMC) and remained in good health during the
entire period of time.
2CMC-treated mice shed virus in feces later than untreated
animals. Stool samples collected from animals throughout these
experiments were used for quantification of viral RNA loads by
qRT-PCR. Samples were collected individually from each animal
between 0 and 11 days p.i. (unless the animal died) (Fig. 6). Stool
samples collected at day 0 had no detectable levels of viral RNA (in
both vehicle- and 2CMC-treated animals). Viral RNA was de-
tected 1 day after infection in the untreated and 2CMC-treated
groups. Thismay possibly reflect the inoculum that had passed the
gastrointestinal tract.
Whereas viral RNA remained undetectable in stool samples of
2CMC-treatedmice at 2 and 3 days p.i., levels of viral RNA in stool
samples of untreated mice increased to 5.5  0.3 log10 copies/g
stool at day 3 (Fig. 6). At 4 days p.i., the viral loads in stool samples
from untreatedmice were as high as 6.2 0.3 log10 copies/g stool.
From4days p.i. onward, an increase in viral RNA titers in the stool
samples of 2CMC-treated mice (to a maximum of 4.7 0.6 log10
copies/g stool at 6 days p.i.) was observed. This maximum viral
load at 6 days p.i. coincided with (i) the slightly lethargic behavior
FIG 2 Effect of 2CMC on Norwalk virus replicon clearance from HG23 cells. (A) In the clearance phase, cells were treated for six consecutive passages with
2CMC (at concentrations of 6.25 to 25 g/ml) in the absence of G418 selective pressure and the ratio of viral RNA to beta-actin RNA was determined (NT, not
tested). (B) In the rebound phase (for cells treated with 25 g/ml 2CMC), 2CMCwas omitted from the culture medium but cells were again cultured under the
selective pressure of G418 (1.25 mg/ml). The graph shows the number of cells/25-cm2 T flask for three consecutive rebound passages with cells from each
clearance passage, namely, passages 2, 4, and 6 (ND, not detected). The dotted line represents the number of cells that was set as the starting point to start a new
culture. Results are representative of two independent experiments.
FIG 3 Survival curves of 2CMC-treated (n  15) and untreated (n  12)
MNV-infected AG129 mice. Treatment with 2CMC (100 mg/kg/day) was ini-
tiated 1 h before infection. The compoundwas administered twice daily by the
subcutaneous route for 7 consecutive days. The graph depicts Kaplan-Meier
survival curves as percent survival versus time postinfection.
FIG 4 Weight variation of MNV-infected AG129 mice treated with 2CMC
(n  15) or left untreated (n  12). The graph shows percent body weight
variation (compared to day 0 p.i.) versus time postinfection and mean values
SEM. Values obtained with 2CMC-treated and untreated groups on the same
days postinfection were compared.
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of the treated animals and (ii) the maximum weight loss (Fig. 4).
Viral RNA levels in the stool of thesemice at 6 days p.i. proved still
significantly lower than those in the stool samples of untreated
mice at 4 days p.i. (P 0.0238). After this peak at 6 days p.i., viral
RNA loads decreased to 2.8 0.6 log10 copies/g stool at 9 days p.i.
(P  0.1763 compared to the LOD) and were undetectable at
day 11.
2CMC treatment decreases viral replication in the intestine
and prevents tissue damage. At 3 days p.i., three 2CMC-treated
and six vehicle-treated infected mice were sacrificed; their small
intestines, proximal colons,mesenteric lymph nodes, spleens, and
lungs were collected for quantification of viral RNA by qRT-PCR.
The viral RNA levels in the organs of the 2CMC-treatedmice were
significantly (3 to 4 log10) lower than those in the corresponding
organs of the vehicle-treated group (Fig. 7A). Histological exam-
ination of the small intestine revealed multifocal necrosis of the
intestinal mucosa, associated with a mild lymphocytic inflamma-
tion in the vehicle-treated mice (Fig. 7B and C). The intestinal
mucosa of 2CMC-treated mice appeared totally normal (Fig. 7D
and E).
Norovirus-infectedmice treatedwith 2CMCdevelop protec-
tive immunity. Two weeks after the cessation of treatment with
2CMC (i.e., 3 weeks after infection), six mice were rechallenged
with MNV. During the next 7 days, animals were weighed daily
and stool samples were collected. All of the animals appeared
healthy during the entire week following the rechallenge, whereas
a control group (n  3) developed disease and had to be eutha-
nized at 3 days p.i. The variation in the weight of mice previously
treated with 2CMC mice was, on average, 2% (not statistically
significant). In stool samples from these drug-treated mice, MNV
RNA remained undetectable during the entire observation period.
DISCUSSION
We reported recently that the HCV nucleoside polymerase inhib-
itor 2CMC inhibits the in vitro replication of MNV (a surrogate
for human norovirus), with EC50s of2M(17).We now report
anti-norovirus activity of 2CMC in the Norwalk virus replicon
model, the single available human norovirus cell culture model.
This nucleoside analogue reducedNorwalk virus replicon replica-
tion in a dose-dependentmanner with an EC50 of5g/ml (20
FIG 5 Fecal consistency of MNV-infected AG129 mice treated with 2CMC or left untreated. Scores for consistency of stool (0, normal feces; 1, mixed stool
samples containing both solid and pasty feces; 2, pasty feces; 3, semiliquid feces; 4, liquid feces) versus time postinfection. Data are expressed as mean values
SEM. In each group, 6 to 15 individual stool samples were collected each day, with the exceptions of the untreated group at 4 days p.i. and the 2CMC-treated
group at 11 days p.i., when 3 stool samples were collected. Values obtained with the 2CMC-treated and untreated groups on the same days postinfection were
compared.
FIG 6 Viral RNA loads in stool samples of 2CMC-treated or untreatedMNV-infected AG129mice. Data are presented as log10 RNA copy numbers per gram of
stool versus time postinfection for untreated or 2CMC-treated animals. In each group, RNA was quantified in 6 to 15 individual stool samples per day, with the
exceptions of the untreated group at 4 days p.i. and the 2CMC-treated group at 11 days p.i., when 3 stool samples were collected. The dotted line represents the
LOD. Values obtained with the 2CMC-treated and untreated groups on the same days postinfection were compared.
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M). Another group recently also reported the in vitro anti-noro-
virus activity of 2CMC; they reported 10-fold lower EC50s, which
may be related to differences in either themethodology used or the
purity of the compound used (the activity of our batch of com-
pound resulted in an inhibition of the replication of an unrelated
virus, i.e., the HCV, comparable to the inhibition reported by
other groups). At a concentration close to the EC90, 2CMC was
able to clear cells of their Norwalk virus replicon following four
consecutive passages of antiviral pressure. Our attempts to select
for resistance to 2CMC in Norwalk virus replicon-carrying cells
were unsuccessful (data not shown), which is in line with our
failure to select 2CMC-resistantMNV (17). Also againstHCV, the
barrier to resistance of this nucleoside analogue is high (23).
We next studied whether 2CMC is able to protect against no-
rovirus-induced morbidity/mortality in a murine infection
model. To this end, we established a model of norovirus infection
and disease in IFN-/ and IFN- receptor-deficient AG129mice
following oral infectionwithMNV-1.CW3. Innate-immunity-de-
ficient mice have been shown to develop severe illness following
MNV infection, with significant mortality in particular when in-
FIG 7 (A) Viral RNA loads in organs of 2CMC-treated or untreated MNV-infected AG129 mice. Data are presented as log10 RNA copy numbers per gram of
organ at 3 days p.i. for the small intestines, large intestines, mesenteric lymph nodes, spleens, and lungs of untreated or 2CMC-treated animals. The dotted line
represents the LOD. An asterisk indicates that a P value of0.05 was determined with the Mann-Whitney test, and medians obtained with 2CMC-treated and
untreated groups at 3 days p.i. were compared. (B to E) Histopathology of the small intestines of 2CMC-treated and untreated MNV-infected AG129 mice.
Images show H&E staining of the small intestines of representative untreated AG129 mice (B and C) and 2CMC-treated mice (D and E) at
50 (B and D) and

200 (C and E) magnifications.
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fected with the MNV-1.CW3 strain (13, 15). MNV-infected
AG129 mice became visibly ill 3 days after oral infection, with
10% body weight loss and diarrhea. Changes in stool consis-
tency were detected from 2 days p.i. onward and progressed to
liquid stool at 4 days p.i., with intense virus shedding and clear
signs (following histological examination of the intestines) of
acute mucosal necrosis. The severity of illness progressed rapidly,
resulting in 100% mortality 4 days after infection (n 12).
The great diversity of norovirus strains and the genetic drift
associated with the more clinically relevant GII.4 strains will re-
quire broad-spectrum norovirus inhibitors. Valopicitabine, the
3=-valyl ester oral prodrug of 2CMC, was shown to markedly re-
duce viral loads in chronically HCV-infected patients (24, 25);
however, its development was halted because of adverse effects.
2CMC, through its 5=-triphosphate metabolite, targets the active
site of the viral RNA-dependent RNA polymerases (18, 26). Since
we demonstrated in vitro inhibitory activity against two geno-
groups of the Norovirus genus, it may be expected that 2CMC (as
well as other 2=-Cmethyl nucleoside analogues) is effective against
the more prevalent GII.4 noroviruses. 2CMC-treated, MNV-in-
fectedAG129mice presented no symptoms and lost less weight up
to 4 days after infection, at which time untreatedmice had died or
been euthanized. 2CMC-treated animals did not become diar-
rheic, and no macroscopic or histological signs of disease were
observed in their intestines. Treated animals developed a mild
disease on days 5 and 6 p.i. and lost significant body weight but
shed less virus than untreated animals did. They finally recovered
fully, and no rebound was observed following the cessation of
treatment at day 7 p.i. It remains to be studied why a viral load
increase in treated animals is apparent on day 4 p.i. Since mice
may eat their feces, reinfection could be the cause of this delayed
viremia. Importantly, the viral RNA levels in the stool samples of
treated mice proved to be significantly lower than those in the
stool samples of untreated mice. Whether the viruses shed in the
stool of 2CMC-treated animals are infectious virus particles was
not assessed in this study.
Since AG129 mice lack key elements of innate immunity, ac-
quired immunity is expected to result in the recovery of 2CMC-
treated animals fromMNV infection.MNV-specific IgG antibod-
ies have been described as potentially neutralizing and have been
shown to play a part in the immune response of MNV-infected
mice, limiting MNV replication in the intestine and spleen (27,
28). We hypothesize that 2CMC limits the replication of MNV in
the gut for a sufficiently long period of time to allow the develop-
ment of neutralizing antibodies that will (together with a T-cell
response) go on to clear the infection. Such protective immunity
should also protect against a rechallenge with MNV. Two weeks
after the cessation of treatment with 2CMC, mice were therefore
rechallenged withMNV. All of the animals remained healthy dur-
ing the week following the rechallenge, without diarrhea, viral
shedding in stool, or significant weight loss. This observation is in
line with previous studies with mice (27, 28). Also in human vol-
unteers who were challenged with a GII human norovirus, a Th1
cellular immune response leading toB-cell differentiation and IgG
production was suggested to be associated with protection from
infection following a challenge (29).
It will be relevant to study the immune response (such as cyto-
kine response, kinetics of antibody production, duration of im-
munity) of these MNV-infected and 2CMC-treated mice.
The use of antiviral drugs to treat symptomatic norovirus in-
fections might be somewhat challenging, given the fact that the
onset of symptoms in humans is just 12 to 48 h after infection and
that themean duration of illness is3 days. However, when given
soon after the start of the first symptoms, a potent drug may be
able to reduce the severity of the illness and, importantly, shed-
ding of infectious virus (thus reducing the chance of transmis-
sion). An anti-norovirus drug would also be very useful for pro-
phylaxis during a norovirus outbreak in communal settings such
as nursing homes and hospitals, where large outbreaks of norovi-
rus often occur (and that may lead to hundreds of affected indi-
viduals). A potent and safe drug may contain the spread of this
highly infectious virus in such settings.
It will also be relevant to assess the impact of treatment with an
antiviral compound (such as 2CMC) on persistent norovirus in-
fections, in particular given the increasingly recognized role of
noroviruses as agents of chronic gastroenteritis in immunocom-
promised patients. To that end, a norovirus model will need to be
used that employs MNV strains that cause a persistent infection.
In conclusion, we have demonstrated, to the best of our knowl-
edge, for the first time that an antiviral molecule protects against
norovirus-induced diarrhea and death in a relevant animalmodel.
This model and reference compound can be employed in future
efforts to develop highly potent, broad-spectrum, and safe anti-
norovirus drugs.
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